Effects of natural and commercial orange juice consumption in inflammatory factors ( hs-CRP; ICAM; VCAM; IL-6; E-Selectin )and endothelial function evaluation (FMD ) in healthy volunteers

Effects of natural and commercial orange juice consumption in blood pressure and inflammatory factors in healthy volunteers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201205079662N2

Enrollment

Registered

2012-06-10

Start date

2012-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Blood pressure. Condition 2: flow-mediated dilatation (FMD). Hypertensive diseases Diseases of arteries, arterioles and capillaries

Interventions

Intervention 1: 500 ml of fresh orange juice consumption in group 1 for 4wk. Intervention 2: 500 ml of Commercial orange juice consumption in group 1, for 4wk.

500 ml of fresh orange juice consumption in group 1 for 4wk

500 ml of Commercial orange juice consumption in group 1, for 4wk.

Eligibility

Sex/Gender

All

Age

19 Years to 59 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Healthy individuals 19-59 years. Exclusion criteria: Individuals with a history of diseases; diabetes; cardiovascular disease; liver and kidney as well as those with thyroid disease; pregnant and breastfeeding; individuals with dyslipidemia, metabolic and endocrine diseases and those with a vegetarian diet.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Positive changes in inflammatory markers. Timepoint: Baseline and after 4 weeks. Method of measurement: ELISA kit.;Positive changes in endothelial function. Timepoint: Baseline and after 4 weeks. Method of measurement: Doppler ultrasonography.	—

Secondary

Measure	Time frame
Decrease in blood pressure. Timepoint: Baseline and after 4 weeks. Method of measurement: Sphygmomanometer.;Positive changes in lipid profiles. Timepoint: Baseline and after 4 weeks. Method of measurement: kit.;Cholesterol Level. Timepoint: Before and after 4 weeks. Method of measurement: KIT.;HDL Level. Timepoint: Before and after 4 weeks. Method of measurement: KIT.;LDL level. Timepoint: Before and after 4 weeks. Method of measurement: KIT.	—

Measure

Time frame

Decrease in blood pressure. Timepoint: Baseline and after 4 weeks. Method of measurement: Sphygmomanometer.;Positive changes in lipid profiles. Timepoint: Baseline and after 4 weeks. Method of measurement: kit.;Cholesterol Level. Timepoint: Before and after 4 weeks. Method of measurement: KIT.;HDL Level. Timepoint: Before and after 4 weeks. Method of measurement: KIT.;LDL level. Timepoint: Before and after 4 weeks. Method of measurement: KIT.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026